CONSUN PHARMAC.GR.HD -10 (F:C1P) — Market Cap & Net Worth
Market Cap & Net Worth: CONSUN PHARMAC.GR.HD -10 (C1P)
CONSUN PHARMAC.GR.HD -10 (F:C1P) has a market capitalization of $1.35 Billion (€1.15 Billion) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #7553 globally and #1045 in its home market, demonstrating a -2.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CONSUN PHARMAC.GR.HD -10's stock price €1.47 by its total outstanding shares 841408111 (841.41 Million). See CONSUN PHARMAC.GR.HD -10 capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
CONSUN PHARMAC.GR.HD -10 Market Cap History: 2015 to 2026
CONSUN PHARMAC.GR.HD -10's market capitalization history from 2015 to 2026. Data shows growth from $1.57 Million to $1.45 Billion (90.46% CAGR).
CONSUN PHARMAC.GR.HD -10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CONSUN PHARMAC.GR.HD -10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.47x
CONSUN PHARMAC.GR.HD -10's market cap is 0.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.50x
CONSUN PHARMAC.GR.HD -10's market cap is 1.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $35.61 Million | $2.04 Billion | $590.17 Million | 0.02x | 0.06x |
| 2022 | $62.17 Million | $2.34 Billion | $682.91 Million | 0.03x | 0.09x |
| 2023 | $201.66 Million | $2.59 Billion | $784.53 Million | 0.08x | 0.26x |
| 2024 | $1.01 Billion | $2.97 Billion | $910.46 Million | 0.34x | 1.11x |
| 2025 | $1.61 Billion | $3.42 Billion | $1.08 Billion | 0.47x | 1.50x |
Competitor Companies of C1P by Market Capitalization
Companies near CONSUN PHARMAC.GR.HD -10 in the global market cap rankings as of August 4, 2026.
Key companies related to CONSUN PHARMAC.GR.HD -10 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
CONSUN PHARMAC.GR.HD -10 Historical Marketcap From 2015 to 2026
Between 2015 and today, CONSUN PHARMAC.GR.HD -10's market cap moved from $1.57 Million to $ 1.45 Billion, with a yearly change of 90.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.45 Billion | -10.37% |
| 2025 | €1.61 Billion | +59.22% |
| 2024 | €1.01 Billion | +402.44% |
| 2023 | €201.66 Million | +224.37% |
| 2022 | €62.17 Million | +74.59% |
| 2021 | €35.61 Million | +325.88% |
| 2020 | €8.36 Million | +6.25% |
| 2019 | €7.87 Million | +110.53% |
| 2018 | €3.74 Million | -26.92% |
| 2017 | €5.12 Million | +205.88% |
| 2016 | €1.67 Million | +6.25% |
| 2015 | €1.57 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of CONSUN PHARMAC.GR.HD -10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.35 Billion USD |
| MoneyControl | $1.35 Billion USD |
| MarketWatch | $1.35 Billion USD |
| marketcap.company | $1.35 Billion USD |
| Reuters | $1.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more